IP Library Granted Patent US 7,851,494
Granted Patent B2
US 7,851,494 · App. 11/772,504 · Granted Dec 14, 2010

Method for the treatment of metabolic disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,851,494
App. No.
11/772,504
Granted
Dec 14, 2010
Kind
B2
Abstract

Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.

Claims (9)

1. A method for treating a mammalian subject with a condition selected from the group consisting of insulin resistance syndrome, Type II Diabetes, and, hyperlipidemia, comprising administering to the subject an amount of a biologically active agent effective to treat the condition, wherein the agent is a compound of the formula:

Wherein

n is 1 or 2;

A is phenyl substituted by 1 or 2 groups selected from the group consisting of: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy.

2. The method of claim 1 , wherein the agent is administered orally.

3. The method of claim 1 , wherein the subject is a human.

4. The method of claim 3 , wherein the agent is administered in an amount from one milligram to four hundred milligrams per day.

5. The method of claim 1 , wherein the compound is 5-[(4-(2,6-difluorobenzyloxy)phenyl)-methyl]-1H-tetrazole.

6. The method of claim 1 , further comprising administering to the subject an effective amount of a therapeutic agent selected from the group consisting of: metformin; glyburide; the combination of metformin and glyburide; atorvastatin; lovastatin; pravastatin; simvastatin; clofibrate; gemfibrozil, rosiglitazone; pioglitazone; acarbose; and repaglinide.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jan 21, 2021
From: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
To: WELLSTAT THERAPEUTICS CORPORATION
Reel/Frame 055056/0891 →
SECURITY AGREEMENT Recorded Sep 18, 2013
From: WELLSTAT THERAPEUTICS CORPORATION
To: PDL BIOPHARMA, INC.
Reel/Frame 031227/0227 →
SECURITY AGREEMENT Recorded Aug 16, 2013
From: WELLSTAT THERAPEUTICS CORPORATION
To: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 031029/0875 →